Table of Contents
International Journal of Proteomics
Volume 2014 (2014), Article ID 532953, 9 pages
http://dx.doi.org/10.1155/2014/532953
Research Article

The Effect of Alendronate on Proteome of Hepatocellular Carcinoma Cell Lines

1National Center for Proteomics, University of Karachi, Karachi 75270, Pakistan
2Dr. Panjwani Center for Molecular Medicine and Drug Research, ICCBS, University of Karachi, Karachi 75270, Pakistan

Received 8 October 2013; Revised 13 December 2013; Accepted 14 December 2013; Published 6 February 2014

Academic Editor: Jen-Fu Chiu

Copyright © 2014 Amber Ilyas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. B. El-Serag and K. L. Rudolph, “Hepatocellular carcinoma: epidemiology and molecular carcinogenesis,” Gastroenterology, vol. 132, no. 7, pp. 2557–2576, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Ferlay, H.-R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008,” International Journal of Cancer, vol. 127, no. 12, pp. 2893–2917, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. W. Alazawi, M. Cunningham, J. Dearden, and G. R. Foster, “Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection,” Alimentary Pharmacology and Therapeutics, vol. 32, no. 3, pp. 344–355, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. R. N. Aravalli, C. J. Steer, and E. N. K. Cressman, “Molecular mechanisms of hepatocellular carcinoma,” Hepatology, vol. 48, no. 6, pp. 2047–2063, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Ebara, M. Ohto, N. Sugiura et al., “Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients,” Journal of Gastroenterology and Hepatology, vol. 5, no. 6, pp. 616–626, 1990. View at Google Scholar · View at Scopus
  6. T. Seki, M. Wakabayashi, T. Nakagawa et al., “Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma,” Cancer, vol. 74, no. 3, pp. 817–825, 1994. View at Google Scholar
  7. O. Matsui, M. Kadoya, J. Yoshikawa et al., “Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization,” Radiology, vol. 188, no. 1, pp. 79–83, 1993. View at Google Scholar · View at Scopus
  8. T. Livraghi, S. N. Goldberg, S. Lazzaroni, F. Meloni, L. Solbiati, and G. S. Gazelle, “Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection,” Radiology, vol. 210, no. 3, pp. 655–661, 1999. View at Google Scholar · View at Scopus
  9. K. M. Swanson and R. J. Hohl, “Anti-cancer therapy: targeting the mevalonate pathway,” Current Cancer Drug Targets, vol. 6, no. 1, pp. 15–37, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. J. L. Goldstein and M. S. Brown, “Regulation of the mevalonate pathway,” Nature, vol. 343, no. 6257, pp. 425–430, 1990. View at Publisher · View at Google Scholar · View at Scopus
  11. P. M. Ghosh, G. E. Mott, N. Ghosh-Choudhury et al., “Lovastatin induces apoptosis by inhibiting mitotic and post-mitotic events in cultured mesangial cells,” Biochimica et Biophysica Acta, vol. 1359, no. 1, pp. 13–24, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Barbacid, “ras genes,” Annual Review of Biochemistry, vol. 56, pp. 779–827, 1987. View at Google Scholar · View at Scopus
  13. J. L. Bos, “The ras gene family and human carcinogenesis,” Mutation Research, vol. 195, no. 3, pp. 255–271, 1988. View at Google Scholar · View at Scopus
  14. N. M. G. M. Appels, J. H. Beijnen, and J. H. M. Schellens, “Development of farnesyl transferase inhibitors: a review,” The Oncologist, vol. 10, no. 8, pp. 565–578, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Koshimune, M. Aoe, S. Toyooka et al., “Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines,” BMC Cancer, vol. 7, article 8, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. M. J. Rogers, J. C. Crockett, F. P. Coxon, and J. Mönkkönen, “Biochemical and molecular mechanisms of action of bisphosphonates,” Bone, vol. 49, no. 1, pp. 34–41, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Fleisch, “Bisphosphonates: pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease,” Drugs, vol. 42, no. 6, pp. 919–944, 1991. View at Google Scholar · View at Scopus
  18. M. Goffinet, M. Thoulouzan, A. Pradines et al., “Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells,” BMC Cancer, vol. 6, article 60, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. A. A. Reszka and G. A. Rodan, “Nitrogen-containing bisphosphonate mechanism of action,” Mini-Reviews in Medicinal Chemistry, vol. 4, no. 7, pp. 711–719, 2004. View at Google Scholar · View at Scopus
  20. R. Takahashi, C. Shimazaki, T. Inaba et al., “A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells,” Leukemia Research, vol. 25, no. 1, pp. 77–83, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. S. G. Senaratne, G. Pirianov, J. L. Mansi, T. R. Arnett, and K. W. Colston, “Bisphosphonates induce apoptosis in human breast cancer cell lines,” British Journal of Cancer, vol. 82, no. 8, pp. 1459–1468, 2000. View at Google Scholar · View at Scopus
  22. M. V. Lee, E. M. Fong, F. R. Singer, and R. S. Guenette, “Bisphosphonate treatment inhibits the growth of prostate cancer cells,” Cancer Research, vol. 61, no. 6, pp. 2602–2608, 2001. View at Google Scholar · View at Scopus
  23. C. M. Shipman, M. J. Rogers, J. F. Apperley, R. G. G. Russell, and P. I. Croucher, “Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity,” British Journal of Haematology, vol. 98, no. 3, pp. 665–672, 1997. View at Google Scholar · View at Scopus
  24. S. S. Virtanen, H. K. Väänänen, P. L. Härkönen, and P. T. Lakkakorpi, “Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway,” Cancer Research, vol. 62, no. 9, pp. 2708–2714, 2002. View at Google Scholar · View at Scopus
  25. S. Muller, E. Migianu, M. Lecouvey, M. Kraemer, and O. Oudar, “Alendronate inhibits proliferation and invasion of human epidermoid carcinoma cells in vitro,” Anticancer Research, vol. 25, no. 4, pp. 2655–2660, 2005. View at Google Scholar · View at Scopus
  26. A. R. Kang, Y. R. Oh, H. Y. Kim et al., “Up-regulation of inhibitors of DNA binding/differentiation gene during alendronate-induced osteoblast differentiation,” Archives of Gynecology and Obstetrics, vol. 285, no. 5, pp. 1331–1338, 2012. View at Publisher · View at Google Scholar
  27. N. Kohno and I. Kokufu, “Prevention of bone metastases from breast cancer by adjuvant bisphosphonate therapy,” Breast Cancer, vol. 10, no. 1, pp. 33–37, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Hashimoto, K.-I. Morishige, K. Sawada et al., “Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model,” Cancer Research, vol. 65, no. 2, pp. 540–545, 2005. View at Google Scholar · View at Scopus
  29. T. Hiraga, P. J. Williams, G. R. Mundy, and T. Yoneda, “The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases,” Cancer Research, vol. 61, no. 11, pp. 4418–4424, 2001. View at Google Scholar · View at Scopus
  30. K. Sawada, K.-I. Morishige, M. Tahara et al., “Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho,” Cancer Research, vol. 62, no. 21, pp. 6015–6020, 2002. View at Google Scholar · View at Scopus
  31. M. Susa, T. Morii, H. Yabe et al., “Alendronate inhibits growth of high-grade chondrosarcoma cells,” Anticancer Research, vol. 29, no. 6, pp. 1879–1888, 2009. View at Google Scholar · View at Scopus
  32. L. Gong, R. B. Altman, and T. E. Klein, “Bisphosphonates pathway,” Pharmacogenetics and Genomics, vol. 21, no. 1, pp. 50–53, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Ebert, S. Zeck, R. Krug et al., “Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation,” Bone, vol. 44, no. 5, pp. 858–864, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. I. Buhaescu and H. Izzedine, “Mevalonate pathway: a review of clinical and therapeutical implications,” Clinical Biochemistry, vol. 40, no. 9-10, pp. 575–584, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Tsubaki, T. Itoh, T. Satou et al., “Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway,” Biochemical Pharmacology, vol. 85, no. 2, pp. 163–172, 2013. View at Publisher · View at Google Scholar
  36. X. Jiang, H. Pan, J. F. Nabhan et al., “A novel EST-derived RNAi screen reveals a critical role for farnesyl diphosphate synthase in β2-adrenergic receptor internalization and down-regulation,” The FASEB Journal, vol. 26, no. 5, pp. 1995–2007, 2012. View at Publisher · View at Google Scholar
  37. R. K. Keller and S. J. Fliesler, “Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of the isoprenoid pathway,” Biochemical and Biophysical Research Communications, vol. 266, no. 2, pp. 560–563, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Amin, S. A. Cornell, S. K. Gustafson et al., “Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis,” Journal of Lipid Research, vol. 33, no. 11, pp. 1657–1663, 1992. View at Google Scholar · View at Scopus
  39. R. Thaler, S. Spitzer, H. Karlic, C. Berger, K. Klaushofer, and F. Varga, “Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells,” Biochemical Pharmacology, vol. 85, no. 2, pp. 173–185, 2013. View at Publisher · View at Google Scholar
  40. C. Gazin, N. Wajapeyee, S. Gobeil, C.-M. Virbasius, and M. R. Green, “An elaborate pathway required for Ras-mediated epigenetic silencing,” Nature, vol. 449, no. 7165, pp. 1073–1077, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. T.-J. Fan, L.-H. Han, R.-S. Cong, and J. Liang, “Caspase family proteases and apoptosis,” Acta Biochimica et Biophysica Sinica, vol. 37, no. 11, pp. 719–727, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Suyama, Y. Noguchi, T. Tanaka et al., “Isoprenoid-independent pathway is involved in apoptosis induced by risedronate, a bisphosphonate, in which Bim plays a critical role in breast cancer cell line MCF-7,” Oncology Reports, vol. 18, no. 5, pp. 1291–1298, 2007. View at Google Scholar · View at Scopus
  43. I. Csiki, K. Yanagisawa, N. Haruki et al., “Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1α in non-small cell lung cancer,” Cancer Research, vol. 66, no. 1, pp. 143–150, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. S. W. Kang, H. Z. Chae, M. S. Seo, K. Kim, I. C. Baines, and S. G. Rhee, “Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generatedin response to growth factors and tumor necrosis factor-α,” Journal of Biological Chemistry, vol. 273, no. 11, pp. 6297–6302, 1998. View at Publisher · View at Google Scholar · View at Scopus
  45. C. K. Sen, “Redox signaling and the emerging therapeutic potential of thiol antioxidants,” Biochemical Pharmacology, vol. 55, no. 11, pp. 1747–1758, 1998. View at Publisher · View at Google Scholar · View at Scopus
  46. D. J. Lee, D. H. Kang, M. Choi et al., “Peroxiredoxin-2 represses melanoma metastasis by increasing E-Cadherin/β-Catenin complexes in adherens junctions,” Cancer Research, vol. 73, no. 15, pp. 1–14, 2013. View at Publisher · View at Google Scholar
  47. J. Furuta, Y. Nobeyama, Y. Umebayashi, F. Otsuka, K. Kikuchi, and T. Ushijima, “Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas,” Cancer Research, vol. 66, no. 12, pp. 6080–6086, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Ai, Y. Tan, W. Ying et al., “Proteome analysis of hepatocellular carcinoma by laser capture microdissection,” Proteomics, vol. 6, no. 2, pp. 538–546, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. I. Arozarena, D. Matallanas, M. T. Berciano et al., “Activation of H-Ras in the endoplasmic reticulum by the RasGRF family guanine nucleotide exchange factors,” Molecular and Cellular Biology, vol. 24, no. 4, pp. 1516–1530, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Takakuwa, S. Nomura, F. Matsuzuka, H. Inoue, and K. Aozasa, “Expression of interleukin-7 and its receptor in thyroid lymphoma,” Laboratory Investigation, vol. 80, no. 10, pp. 1483–1490, 2000. View at Google Scholar · View at Scopus
  51. V. Paleri, A. Pulimood, G. R. Davies, and M. A. Birchall, “Interleukins 7 and 12 are expressed in head and neck squamous cancer,” Clinical Otolaryngology and Allied Sciences, vol. 26, no. 4, pp. 302–306, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. P. Trinder, “Constitutive and IFN-γ regulated expression of IL-7 and IL-15 in human renal cell cancer,” International Journal of Oncology, vol. 14, no. 1, pp. 23–31, 1999. View at Google Scholar · View at Scopus
  53. M. Oka, K. Hirose, N. Iizuka et al., “Cytokine mRNA expression patterns in human esophageal cancer cell lines,” Journal of Interferon and Cytokine Research, vol. 15, no. 11, pp. 1005–1009, 1995. View at Google Scholar · View at Scopus
  54. T. Takeuchi, H. Yamanouchi, Q. Yue, and Y. Ohtsuki, “Epithelial component of lymphoid stroma-rich Warthin's tumour expresses interleukin (IL)-7,” Histopathology, vol. 32, no. 4, pp. 383–384, 1998. View at Google Scholar · View at Scopus
  55. B. M. J. Foxwell, C. Beadling, D. Guschin, I. Kerr, and D. Cantrell, “Interleukin-7 can induce the activation of Jak 1, Jak 3 and STAT 5 proteins in murine T cells,” European Journal of Immunology, vol. 25, no. 11, pp. 3041–3046, 1995. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Toker and L. C. Cantley, “Signalling through the lipid products of phosphoinositide-3-OH kinase,” Nature, vol. 387, no. 6634, pp. 673–676, 1997. View at Publisher · View at Google Scholar · View at Scopus
  57. B. Vanhaesebroeck, S. J. Leevers, G. Panayotou, M. D. Waterfield, and M. D. Waterfield, “Phosphoinositide 3-kinases: a conserved family of signal transducers,” Trends in Biochemical Sciences, vol. 22, no. 7, pp. 267–272, 1997. View at Publisher · View at Google Scholar · View at Scopus